The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Iron dysregulation in movement disorders
Open accessAbstract
Iron is an essential element necessary for energy production, DNA and neurotransmitter synthesis, myelination and phospholipid metabolism. Neurodegeneration with brain iron accumulation (NBIA) involves several genetic disorders, two of which, aceruloplasminemia and neuroferritinopathy, are caused by mutations in genes directly involved in iron metabolic pathway, and others, such as pantothenate-kinase 2, phospholipase-A2 and fatty acid 2-hydroxylase associated neurodegeneration, are caused by mutations in genes coding for proteins involved in phospholipid metabolism. Phospholipids are major constituents of myelin and iron accumulation has been linked to myelin derangements. Another group of NBIAs is caused by mutations in lysosomal enzymes or transporters such as ATP13A2, mucolipin-1 and possibly also β-galactosidase and α-fucosidase. Increased cellular iron uptake in these diseases may be caused by impaired recycling of iron which normally involves lysosomes. Abnormal iron utilization by mitochondria, as has been proposed in Friedreich's ataxia, is another possible mechanism of iron accumulation. Other, more common degenerative movement disorders, such as Parkinson's disease, Huntington's disease, multiple system atrophy and progressive supranuclear palsy also exhibit increased brain iron content. Finally, brain iron deficiency has been implicated in restless legs syndrome. This review provides an update on recent findings related to genetics, pathogenic mechanisms, diagnosis, and treatment of movement disorders associated with dysregulation of brain iron. We also propose a new classification of NBIAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Papp, M. I., Kahn, J. E., & Lantos, P. L. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90219-0 · Cited by 991
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882
Puccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P., & Koenig, M. (2001) · Nature Genetics · doi:10.1038/84818 · Cited by 738
MRI measurement of brain iron in patients with restless legs syndrome
Allen, R. P., Barker, P. B., Wehrl, F., Song, H. K., & Earley, C. J. (2001) · Neurology · doi:10.1212/wnl.56.2.263 · Cited by 570
Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux
Harris, Z. L., Durley, A. P., Man, T. K., & Gitlin, J. D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10812 · Cited by 568
Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.
Harris, Z. L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R. T., & Gitlin, J. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2539 · Cited by 558
Curtis, A. R. J., Fey, C., Morris, C. M., Bindoff, L. A., Ince, P. G., Chinnery, P. F., Coulthard, A., Jackson, M. J., Jackson, A. P., McHale, D. P., et al. (2001) · Nature Genetics · doi:10.1038/ng571 · Cited by 537
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains
Connor, J. R., Menzies, S. L., Martin, S. M. S., & Mufson, E. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270421 · Cited by 472
Hepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466
Selective iron chelation in Friedreich ataxia: biologic and clinical implications
Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007) · Blood · doi:10.1182/blood-2006-12-065433 · Cited by 409
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401
Clinical and genetic delineation of neurodegeneration with brain iron accumulation
Gregory, A., Polster, B. J., & Hayflick, S. J. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061929 · Cited by 364
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Zheng, W., & Monnot, A. D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.006 · Cited by 302
The role of iron in restless legs syndrome
Allen, R. P., & Earley, C. J. (2007) · Movement Disorders · doi:10.1002/mds.21607 · Cited by 280
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications
Bartzokis, G., Lu, P. H., Tishler, T. A., Fong, S. M., Oluwadara, B., Finn, J. P., Huang, D., Bordelon, Y., Mintz, J., & Perlman, S. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9352-7 · Cited by 238
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229
Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation
Chinnery, P. F., Crompton, D. E., Birchall, D., Jackson, M. J., Coulthard, A., Lombes, A., Quinn, N., Wills, A., Fletcher, N., Mottershead, J. P., et al. (2006) · Brain · doi:10.1093/brain/awl319 · Cited by 205
Nguyen, T., Hamby, A., & Massa, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502177102 · Cited by 194
Increased basal ganglia iron levels in Huntington disease
Bartzokis, G., Cummings, J., Perlman, S., Hance, D. B., & Mintz, J. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.569 · Cited by 183
Use of desferrioxamine in the treatment of aceruloplasminemia
Miyajima, H., Takahashi, Y., Kamata, T., Shimizu, H., Sakai, N., & Gitlin, J. D. (1997) · Annals of Neurology · doi:10.1002/ana.410410318 · Cited by 173
Neurodegeneration with brain iron accumulation–clinical syndromes and neuroimaging
Schipper, H. M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.06.016 · Cited by 141
Zhang, Y., Mikhael, M., Xu, D., Li, Y., Soe-Lin, S., Ning, B., Li, W., Nie, G., Zhao, Y., & Ponka, P. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3129 · Cited by 120
Faucheux, B. A., Martin, M., Beaumont, C., Hunot, S., Hauw, J., Agid, Y., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01118.x · Cited by 116
Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease
Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., Zeiler, B., Bornemann, A., Pahnke, J., Becker, G., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000144276.29988.c3 · Cited by 111
Genetics of neurodegeneration with brain iron accumulation
Gregory, A., & Hayflick, S. J. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0181-3 · Cited by 104
Intravenous iron dextran for severe refractory restless legs syndrome
Ondo, W. G. (2010) · Sleep Medicine · doi:10.1016/j.sleep.2009.12.002 · Cited by 68
Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation
Kwiatkowski, A., Ryckewaert, G., Jissendi Tchofo, P., Moreau, C., Vuillaume, I., Chinnery, P. F., Destée, A., Defebvre, L., & Devos, D. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.024 · Cited by 41
The chemical form of mitochondrial iron in Friedreich’s ataxia
Popescu, B. F. G., Pickering, I. J., George, G. N., & Nichol, H. (2007) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.03.004 · Cited by 36
Cited by
Iron metabolism in the CNS: implications for neurodegenerative diseases
Rouault, T. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3453 · Cited by 496
Sensory aspects of movement disorders
Patel, N., Jankovic, J., & Hallett, M. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70213-8 · Cited by 343
Self-citationThe hallmarks of Parkinson's disease
Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · The FEBS Journal · doi:10.1111/febs.12335 · Cited by 300
Eid, R., Arab, N. T. T., & Greenwood, M. T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.002 · Cited by 288
Serum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study
Pichler, I., Del Greco M., F., Gögele, M., Lill, C. M., Bertram, L., Do, C. B., Eriksson, N., Foroud, T., Myers, R. H., PD GWAS Consortium, et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001462 · Cited by 173
“accumulation in the brain of PD patients [2,3], epidemiological”
Background
Metadata
- Authors
- Dusek, P., Jankovic, J., & Le, W.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 46
- Issue
- 1
- Pages
- 1-18
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2088820046
- Cited by
- 169
- References
- 32
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.